drugset / Trial / NCT00051077

Treatment of Hepatitis in Patients Who Are Triple-Infected With HIV, Hepatitis B Virus (HBV), and Hepatitis C Virus (HCV)

NCT00051077 ↗

RandomizedFactorialDouble-blindTreatment

Summary

This study will investigate the safety and effectiveness of using adefovir dipivoxil (ADV), pegylated interferon (PEG-INF), and ribavirin (RBV) in patients triple-infected with hepatitis B virus (HBV), hepatitis C virus (HCV), and HIV. Patients in this study must be taking lamivudine (3TC).

Timeline

Start
—
Primary completion
—
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Adefovir dipivoxil Small molecule — —
Subject Peginterferon alfa-2a Protein / enzyme biologic — Subcutaneous
Subject Ribavirin Small molecule — Oral